DK0423697T3 - Lipidemulsion indeholdende en prostaglandinanalog - Google Patents

Lipidemulsion indeholdende en prostaglandinanalog

Info

Publication number
DK0423697T3
DK0423697T3 DK90119772.3T DK90119772T DK0423697T3 DK 0423697 T3 DK0423697 T3 DK 0423697T3 DK 90119772 T DK90119772 T DK 90119772T DK 0423697 T3 DK0423697 T3 DK 0423697T3
Authority
DK
Denmark
Prior art keywords
emulsion containing
prostaglandin analogue
lipid emulsion
analogue
prostaglandin
Prior art date
Application number
DK90119772.3T
Other languages
English (en)
Inventor
Yutaka Mizushima
Toshihide Inomata
Arata Yasuda
Original Assignee
Asahi Glass Co Ltd
Seikagaku Kogyo Co Ltd
Yutaka Mizushima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Glass Co Ltd, Seikagaku Kogyo Co Ltd, Yutaka Mizushima filed Critical Asahi Glass Co Ltd
Application granted granted Critical
Publication of DK0423697T3 publication Critical patent/DK0423697T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK90119772.3T 1989-10-16 1990-10-15 Lipidemulsion indeholdende en prostaglandinanalog DK0423697T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1266230A JP2602964B2 (ja) 1989-10-16 1989-10-16 プロスタグランジン類縁体およびその脂肪乳剤

Publications (1)

Publication Number Publication Date
DK0423697T3 true DK0423697T3 (da) 1995-05-29

Family

ID=17428079

Family Applications (2)

Application Number Title Priority Date Filing Date
DK90119772.3T DK0423697T3 (da) 1989-10-16 1990-10-15 Lipidemulsion indeholdende en prostaglandinanalog
DK94111337T DK0624574T3 (da) 1989-10-16 1990-10-15 Hidtil ukendte prostaglandinanaloger

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94111337T DK0624574T3 (da) 1989-10-16 1990-10-15 Hidtil ukendte prostaglandinanaloger

Country Status (10)

Country Link
US (1) US5120870A (da)
EP (2) EP0624574B1 (da)
JP (1) JP2602964B2 (da)
AT (2) ATE117989T1 (da)
AU (1) AU641436B2 (da)
CA (1) CA2027351C (da)
DE (2) DE69016567T2 (da)
DK (2) DK0423697T3 (da)
ES (2) ES2132279T3 (da)
GR (2) GR3015963T3 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0695741B1 (en) * 1994-01-18 2004-06-16 Teijin Limited 7-thiaprostaglandins and process for producing the same
CN1191832C (zh) * 1997-08-27 2005-03-09 三菱制药株式会社 血管生成促进剂
US6632958B1 (en) 1998-06-04 2003-10-14 Mitsubishi Pharma Corporation Process for producing a purified prostaglandin derivative
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
EP1711163A2 (en) * 2004-02-05 2006-10-18 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
AU2005304035B2 (en) * 2004-11-09 2010-07-22 Santen Sas Ophthalmic oil-in-water type emulsion with stable positive zeta potential
EP1655021B1 (en) 2004-11-09 2008-10-29 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
PL1937212T3 (pl) * 2005-10-10 2011-02-28 Santen Sas Emulsje oftalmiczne zawierające prostaglandyny
US8334321B2 (en) 2006-09-05 2012-12-18 Q.P. Corporation Prostaglandin fat emulsion, method for producing the same, method for stabilizing the same, and emulsifying agent
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363817A (en) * 1981-08-27 1982-12-14 Miles Laboratories, Inc. Enol acylate analogs of E1 and E2 prostaglandins
JPS58222014A (ja) * 1982-06-18 1983-12-23 Taisho Pharmaceut Co Ltd プロスタグランジンｅ↓１脂肪乳剤
JPS59216820A (ja) * 1983-05-20 1984-12-06 Taisho Pharmaceut Co Ltd プロスタグランジン脂肪乳剤
JPH0818989B2 (ja) * 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
JPS61151126A (ja) * 1984-12-25 1986-07-09 Teijin Ltd △７―プロスタグランジンａ１類を有効成分として含有する注射用の脂肪乳剤

Also Published As

Publication number Publication date
EP0423697B1 (en) 1995-02-01
ES2070238T3 (es) 1995-06-01
DE69033069D1 (de) 1999-05-27
CA2027351C (en) 2001-06-19
DE69033069T2 (de) 1999-08-19
AU6452690A (en) 1991-04-18
GR3015963T3 (en) 1995-07-31
EP0423697A2 (en) 1991-04-24
GR3030718T3 (en) 1999-11-30
EP0423697A3 (en) 1992-08-05
CA2027351A1 (en) 1991-04-17
DE69016567D1 (de) 1995-03-16
DK0624574T3 (da) 1999-10-25
ES2132279T3 (es) 1999-08-16
JP2602964B2 (ja) 1997-04-23
EP0624574B1 (en) 1999-04-21
EP0624574A2 (en) 1994-11-17
ATE179169T1 (de) 1999-05-15
JPH03204853A (ja) 1991-09-06
AU641436B2 (en) 1993-09-23
US5120870A (en) 1992-06-09
ATE117989T1 (de) 1995-02-15
EP0624574A3 (en) 1995-01-18
DE69016567T2 (de) 1995-09-21

Similar Documents

Publication Publication Date Title
DK0423697T3 (da) Lipidemulsion indeholdende en prostaglandinanalog
NO914092D0 (no) Fremgangsmaate for fremstilling av mercaptoacetylamidderivater
NO905608L (no) Fremgangsmaate for fremstilling av a-nor-steroid-3-karboksylsyrederivater.
ATE188704T1 (de) Phosphonsäurediester-derivat
ES2054732T3 (es) Un procedimiento para preparar un derivado peptidico.
ES2058176T3 (es) Un procedimiento para preparar un derivado peptidico.
FI901277A0 (fi) 2,5,6,7-tetranor-4,8-inter-m-fenylen pg1z-derivativ.
ES537558A0 (es) Un procedimiento para la preparacion del isomero r (dextrogiro)
DE3677465D1 (de) N-glykolylneuraminsaeurederivat.
SE8704542D0 (sv) New derivatives of cysteine
DE3277199D1 (de) Fluorinated diamino-heptene and -heptyne derivatives
ATE82748T1 (de) Verfahren und zwischenprodukte.
ES2095831T3 (es) Acidos tetrahidro-4-fenilimino-3-tiofeno-aceticos.
DE58909563D1 (de) 3-Anilino-2-hydroxycarbonyl-4-thiophenessigsäuren
AU5977980A (en) Aminodeoxyclavulanic acids